Characterized epitope-mapped antibodies
Validated for clinical samples according to ICH and FDA guidelines
Human serum based calibrators & controls
Proprietary products - in-house R&D and production
Personal and competent customer service

SERVICE MEASUREMENTS available
BIOMEDICA develops and produces internationally recognized high quality ELISA kits for clinical research in the field of cardiorenal diseases as well as bone and mineral disorders.

Our customers include numerous top ranking scientific institutions worldwide, well-known CROs and laboratories in the pharmaceutical industry. We are setting the standard for clinical research using serum-based calibrators and controls, thus enabling researchers to collect biologically reliable data. The provided immunoassays are fully validated. Biomedica’s experienced and qualified team of professionals provides technical and scientific support.

The company’s manufacturing processes comply with ISO 9001:2015 management system standards and conform to GMP/GLP guidelines.

For specific markers, Biomedica has become a market leader with a continuously growing portfolio. A worldwide distribution network has been established for these products as well as an analytical service, which offers customers in-house diagnostic analysis of their samples.

**Analytical Testing Service**

Biomedica offers a comprehensive testing service for all our proprietary ELISAs as well as assays from other brands including Luminex testing services.

As an experienced ELISA assay developer and manufacturer located in the heart of Europe, our staff contribute to every step in the making of our ELISAs, thereby gaining a unique understanding of the assays’ performance.

Using our analytical customized testing service, even customers without access to a fully equipped laboratory or skilled staff are able to obtain reliable biomarker results from samples of both human and animal origin.

**Advantages**

- ✔ High-quality services
- ✔ Comprehensive results report
- ✔ Expert sample handling
- ✔ Experienced, trained staff
<table>
<thead>
<tr>
<th>ELISA Name</th>
<th>Key areas</th>
<th>Related diseases</th>
<th>Measures</th>
<th>Sample type</th>
<th>Assay time</th>
<th>Sample volume</th>
<th>Use</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human Vanin-1 (Urine) ELISA</td>
<td>nephrology</td>
<td>acute kidney injury, diabetic nephropathy, drug-induced acute kidney injury, hydronephrosis</td>
<td>human Vanin-1</td>
<td>urine</td>
<td>4.5 hr</td>
<td>10µl / well</td>
<td>research use only</td>
<td>3 (product specific)</td>
</tr>
<tr>
<td>Vanin-1 Mouse/Rat ELISA</td>
<td>nephrology</td>
<td>acute kidney injury, diabetic nephropathy, drug-induced acute kidney injury, hydronephrosis</td>
<td>mouse and rat Vanin-1</td>
<td>mouse and rat serum, plasma and urine</td>
<td>4.5 hr</td>
<td>5µl / well</td>
<td>research use only</td>
<td></td>
</tr>
<tr>
<td>Intact FGF23 ELISA</td>
<td>bone and phosphate metabolism, nephrology, cardiovascular homeostasis</td>
<td>hypophosphatemia, vitamin D disorders, autosomal dominant hypophosphatemia (ADHR), X-linked hypophosphatemia (XLH), fibrous dysplasia of the bone</td>
<td>intact FGF23</td>
<td>human plasma (EDTA, citrate, heparin), protocol for human serum, urine and cell culture supernatant</td>
<td>3.5 hr</td>
<td>50µl / well</td>
<td>research use only</td>
<td>12 (product specific)</td>
</tr>
<tr>
<td>C-terminal FGF23 ELISA</td>
<td>bone and phosphate metabolism, nephrology, cardiovascular homeostasis</td>
<td>hypophosphatemia, vitamin D disorders, autosomal dominant hypophosphatemia (ADHR), X-linked hypophosphatemia (XLH), fibrous dysplasia of the bone</td>
<td>intact and the C-terminal fragment of FGF23</td>
<td>human serum and plasma (EDTA, citrate, heparin)</td>
<td>overnight assay</td>
<td>50µl / well</td>
<td>research use only</td>
<td>40 (product specific)</td>
</tr>
<tr>
<td>Sclerostin ELISA</td>
<td>bone and mineral metabolism</td>
<td>bone and vascular diseases, osteoporosis, cancer induced bone diseases, renal disorders</td>
<td>Wnt-signalling antagonist Sclerostin (SOST)</td>
<td>human serum and plasma (EDTA, heparin), cell culture and urine protocol</td>
<td>overnight assay</td>
<td>20µl / well</td>
<td>research use only</td>
<td>275+ (product specific)</td>
</tr>
</tbody>
</table>
### Bioactive Sclerostin ELISA

**Cat. No. BI-20472**

**Key areas:** bone and mineral metabolism  
**Related diseases:** bone and vascular disease, osteoporosis, cancer induced bone diseases, renal disorders  
**Measures:** bioactive Sclerostin and Sclerostin fragments; antibody binding occurs in the LRP5/6 binding region  
**Sample type:** human serum and plasma (EDTA, citrate), cell culture and urine protocol  
**Assay time:** 3.5 hrs  
**Sample volume:** 20µl / well  
**Use:** research use only  
**References:** 160+ (product specific)

### DKK-1 ELISA

**Cat. No. BI-20413**

**Key areas:** bone and mineral metabolism  
**Related diseases:** osteoporosis, rheumatoid arthritis, cancer induced bone diseases, vascular calcification, diabetes  
**Measures:** Wnt-signalling antagonist Dickkopf-1  
**Sample type:** human serum  
**Assay time:** 3.5 hrs  
**Sample volume:** 20µl / well  
**Use:** research use only  
**References:** 160+ (product specific)

### Periostin ELISA

**Cat. No. BI-20433**

**Key areas:** bone homeostasis, tissue development and repair  
**Related diseases:** osteoporosis, cancer induced bone diseases, cardiovascular diseases, hypertension, respiratory diseases  
**Measures:** all known isoforms of human Periostin  
**Sample type:** human serum and plasma (EDTA, citrate, heparin), cell culture and urine protocol  
**Assay time:** 5.5 hrs  
**Sample volume:** 10µl / well  
**Use:** research use only  
**References:** 21 (product specific)

### Periostin Mouse ELISA

**Cat. No. BI-20433MS**

**Key areas:** bone homeostasis, tissue development and repair  
**Related diseases:** osteoporosis, cancer induced bone diseases, cardiovascular diseases, hypertension, respiratory diseases  
**Measures:** mouse Periostin  
**Sample type:** mouse serum and plasma, cell culture supernatant protocol  
**Assay time:** 4.5 hrs  
**Sample volume:** ≤ 5µl / well  
**Use:** for pre-clinical use  
**References:** 3 (product specific)

### Free sRANKL ELISA

**Cat. No. BI-20462**

**Key areas:** bone and mineral metabolism, thermoregulation  
**Related diseases:** osteoporosis, diseases with locally increased resorption activity, arthritis, type 2 diabetes, cancer induced bone diseases  
**Measures:** soluble, uncomplexed receptor RANKL (receptor activator of NF-kB)  
**Sample type:** human serum and plasma (heparin)  
**Assay time:** overnight assay  
**Sample volume:** 150µl / well  
**Use:** research use only  
**References:** 295+ (product specific)
### Osteoprotegerin (OPG) ELISA

**Cat. No. BI-20403**

**Key areas:** bone and mineral metabolism

**Related diseases:** bone and mineral metabolism, osteoporosis, arthritis, diseases with locally increased resorption activity, cardiovascular disease, vascular calcification

**Measures:** monomeric and dimeric Osteoprotegerin

**Sample type:** human serum and plasma (EDTA, heparin, citrate)

**Assay time:** 5.5 hrs

**Sample volume:** 20µl / well

**Use:** research use only

**References:** 245+ (product specific)

### Soluble Semaphorin 4D ELISA

**Cat. No. BI-20405**

**Key areas:** bone homeostasis, immune response, cell migration, vascularisation, neural connectivity, tumor progression

**Related diseases:** osteoporosis, arthritis, type 2 diabetes, cancer related bone diseases, neurological diseases

**Measures:** soluble SEMA4D/CD100

**Sample type:** human plasma (EDTA, citrate, heparin), cell culture protocol

**Assay time:** 4.5 hrs

**Sample volume:** 10µl / well

**Use:** research use only

**References:** 4 (product specific)

### Total Soluble Neuropilin-1 ELISA

**Cat. No. BI-20409**

**Key areas:** immunology, osteology, cardiology, nephrology, oncology

**Related diseases:** kidney disease, cardiovascular disease, cancer

**Measures:** total soluble NRP1

**Sample type:** human serum and plasma (EDTA, citrate, heparin), protocol for cell culture supernatant, urine, and non-human samples

**Assay time:** 4 hrs

**Sample volume:** 10µl / well

**Use:** research use only

**References:** 5 (product specific)

### Endostatin ELISA

**Cat. No. BI-20742**

**Key areas:** angiogenesis, cardiovascular homeostasis

**Related diseases:** artherosclerosis, chronic kidney disease (CKD), ischemia, stroke, micro-vascular injury, renal fibrosis, preeclampsia

**Measures:** angiogenesis inhibitor Endostatin

**Sample type:** human serum and plasma (EDTA, citrate, heparin)

**Assay time:** 4.5 hrs

**Sample volume:** 10µl / sample

**Use:** research use only

**References:** 4 (product specific)

### Endostatin Mouse/Rat ELISA

**Cat. No. BI-20742MR**

**Key areas:** angiogenesis, cardiovascular homeostasis

**Related diseases:** artherosclerosis, chronic kidney disease (CKD), ischemia, stroke, micro-vascular injury, renal fibrosis, preeclampsia

**Measures:** angiogenesis inhibitor Endostatin in mouse and rats

**Sample type:** mouse and rat serum and plasma (EDTA, citrate, heparin)

**Assay time:** 2.5 hrs

**Sample volume:** 5µl / sample

**Use:** for pre-clinical use

**References:** 2 (product specific)
<table>
<thead>
<tr>
<th>ELISA</th>
<th>Key areas</th>
<th>Related diseases</th>
<th>Measures</th>
<th>Sample type</th>
<th>Assay time</th>
<th>Sample volume</th>
<th>Use</th>
<th>References</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>NT-proCNP ELISA</td>
<td>angiogenesis, growth, skeletal development, cardiovascular homeostasis</td>
<td>cardiovascular disease, renal disorders, sepsis, SIRS, pre-eclampsia</td>
<td>NT-proCNP (AA 24-73)</td>
<td>human serum and plasma (EDTA, citrate, heparin), protocol for cell culture supernatant, urine, and non-human samples</td>
<td>4 hrs</td>
<td>20µl / well</td>
<td>research use only</td>
<td>46</td>
<td>(product specific)</td>
</tr>
<tr>
<td>NT-proANP ELISA</td>
<td>cardiovascular homeostasis, cardiotoxicity in preclinical studies</td>
<td>cardiovascular disease, heart failure, transplants, sepsis</td>
<td>NT-proANP (AA 1-98)</td>
<td>human, rat, mouse, cat and dog serum and plasma (EDTA, heparin), cell culture supernatant, urine</td>
<td>3.5 hrs</td>
<td>10µl / well</td>
<td>research use only</td>
<td>161</td>
<td>(product specific)</td>
</tr>
<tr>
<td>NT-proBNP ELISA</td>
<td>cardiovascular and renal homeostasis, regulation of fatty acid metabolism</td>
<td>obesity, diabetes, renal failure, cardiac impairment, acute myocardial infarction, secondary hypertension</td>
<td>NT-proBNP (AA 1-76)</td>
<td>human serum and plasma (EDTA)</td>
<td>3.5 hrs</td>
<td>50µl / well</td>
<td>research use only</td>
<td>107</td>
<td>(product specific)</td>
</tr>
<tr>
<td>NT-proBNP Rat ELISA</td>
<td>cardiovascular and renal homeostasis, regulation of fatty acid metabolism</td>
<td>obesity, diabetes, renal failure, cardiac impairment, acute myocardial infarction, secondary hypertension</td>
<td>NT-proBNP (AA 1-76)</td>
<td>rat serum and plasma</td>
<td>3.5 hrs</td>
<td>10µl / well</td>
<td>research use only</td>
<td>60</td>
<td>(product specific)</td>
</tr>
<tr>
<td>BNP fragment ELISA</td>
<td>cardiovascular homeostasis, renal homeostasis, regulation of fatty acid metabolism</td>
<td>obesity, diabetes, renal failure, cardiac impairment, acute myocardial infarction, secondary hypertension</td>
<td>NT-proBNP (AA 1-76) and all fragments containing AA 8-29 of NT-proBNP</td>
<td>human serum and plasma (EDTA, citrate, heparin)</td>
<td>overnight assay</td>
<td>30µl / well</td>
<td>research use only</td>
<td>60</td>
<td>(product specific)</td>
</tr>
</tbody>
</table>
**Angiopoietin-2 ELISA**

Cat. No. BI-ANG2

Key areas: vascularisation, angiogenesis, inflammation, micro-vascular injury, renal fibrosis, tumor progression

Related diseases: cardiovascular diseases, chronic kidney disease, autoimmune disease, cancer

Measures: human Angiopoietin-2

Sample type: human serum and plasma (EDTA, citrate, heparin)

Assay time: 3.5 hrs

Sample volume: 20µl / well

Use: research use only

References: 3 (product specific)

---

**Angiopoietin-2 Mouse/Rat ELISA**

Cat. No. BI-ANG2MR

Key areas: vascularisation, angiogenesis, inflammation, micro-vascular injury, renal fibrosis, tumor progression

Related diseases: cardiovascular disease, chronic kidney disease, autoimmune disease, cancer

Measures: mouse and rat Angiopoietin-2

Sample type: mouse and rat serum and plasma

Assay time: 5.5 hrs

Sample volume: 5µl / well

Use: research use only

---

**IL-6 ELISA**

Cat. No. BI-IL6

Key areas: inflammation, cancer, cardiology, nephrology, bone metabolism

Related diseases: sepsis, rheumatoid arthritis, systemic juvenile idiopathic arthritis, Casteleman's disease, metabolic syndrome, Covid-19

Measures: human IL-6

Sample type: serum, plasma (EDTA, heparin, citrate), cc supernatant, urine

Assay time: 4.5 hrs

Sample volume: 100µl / well

Use: research use only

References: 79 (product specific)

---

**VEGF ELISA**

Cat. No. BI-VEGF

Key areas: cancer, angiogenesis, inflammation, cardiology, bone metabolism

Related diseases: rheumatoid arthritis, psoriasis, psoriatic arthritis, diabetes and diabetic kidney disease, diabetic retinopathy, obesity

Measures: human VEGF (all circulating isoforms incl. VEGF165b)

Sample type: serum, plasma (EDTA, heparin), cc supernatant, urine

Assay time: 4.5 hrs

Sample volume: 10µl / well

Use: research use only
OxyStat Assay  
Cat. No. BI-5007

Key areas: oxidative stress, cardiology  
Related diseases: cardiovascular diseases

Measures: biological peroxides  
Sample type: human serum, EDTA plasma, biological fluids  
Assay time: 15 min  
Sample volume: 10µl / well  
Use: research use only  
References: 55 (product specific)

oLAB ELISA  
(Anti oxidized LDL autoantibodies)  
Cat. No. BI-20032

Key areas: oxidative stress, cardiology  
Related diseases: cardiovascular diseases

Measures: autoantibodies to oxidized human low density lipoprotein (LDL)  
Sample type: human serum  
Assay time: 2 hrs  
Sample volume: 20µl / well  
Use: research use only  
References: 70 (product specific)